StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2025, quý kết thúc ngày Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Adaptimmune Therapeutics's enterprise value was $55.27M on Oct 19, 2026, against $79.45M a year earlier. Over the last 5 years it ranged from $9.31M to $3.65B, with a median of $846.49M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$55.27M+34.9%
2025Dec 31, 2025$40.96M-94.1%
2024Dec 31, 2024$690.72M-24.5%
2023Dec 29, 2023$915.00M-25.8%
2022Dec 30, 2022$1.23B-62.3%
2021Dec 31, 2021$3.27B-28.9%
2020Dec 31, 2020$4.60B+607.8%
2019Dec 31, 2019$649.97M-80.7%
2018Dec 31, 2018$3.36B-4.4%
2017Dec 29, 2017$3.52B+136.0%
2016Dec 30, 2016$1.49B-69.5%
2015Dec 31, 2015$4.89B–

More Adaptimmune Therapeutics figures

See a number that looks wrong?